Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology
|
Buy Now
EGFR-Directed Therapy in Lung Cancer (Paperback)
Loot Price: R531
Discovery Miles 5 310
|
|
EGFR-Directed Therapy in Lung Cancer (Paperback)
Series: Elements in Molecular Oncology
(sign in to rate)
Loot Price R531
Discovery Miles 5 310
Expected to ship within 12 - 17 working days
|
Donate to Against Period Poverty
Total price: R551
Discovery Miles: 5 510
|
Epidermal growth factor receptor (EGFR)-mutant non-small cell lung
cancer (NSCLC) is a clinically important driver alteration
affecting approximately one-third of lung cancer patients.
Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have
evolved over the last decade from first-generation reversible
tyrosine kinase inhibitors (TKI) to third-generation irreversible
TKIs, of which osimertinib has been the widely accepted as
first-line therapy. Despite survival improvement seen with
osimertinib and its efficacy against acquired T790M mutation,
resistance through on-target and off-target pathways eventually
develop. This Element describes the structural biology and
pathophysiology of EGFR-mutant NSCLC and discusses past, current,
and future treatment options in the metastatic, neoadjuvant, and
adjuvant settings. It describes the biology and recently approved
treatment for EGFR-exon 20 insertion mutation and the treatment for
the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations.
It also outlines the promising clinical applications of circulating
tumor DNA (ctDNA).
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
You might also like..
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.